REVERCE: Randomized Phase II Study of Regorafenib Followed by Cetuximab Versus the Reverse Sequence for Metastatic Colorectal Cancer Patients Previously Treated With Fluoropyrimidine, Oxaliplatin, and Irinotecan

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2018年 / 16卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：12 / 14
页数：3
相关论文
共 50 条
  • [1] Reverce: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan.
    Shitara, Kohei
    Yamanaka, Takeharu
    Denda, Tadamichi
    Tsuji, Yasushi
    Shinozaki, Katsunori
    Komatsu, Yoshito
    Kobayashi, Yoshimitsu
    Furuse, Junji
    Okuda, Hiroyuki
    Asayama, Masako
    Akiyoshi, Kohei
    Kagawa, Yoshinori
    Kato, Takeshi
    Oki, Eiji
    Ando, Takashi
    Ohashi, Yasuo
    Yoshino, Takayuki
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [2] REVERCE: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan: Quality of life analysis
    Yoshino, T.
    Yamanaka, T.
    Denda, T.
    Tsuji, Y.
    Shinozaki, K.
    Komatsu, Y.
    Kobayashi, Y.
    Furuse, J.
    Okuda, H.
    Asayama, M.
    Akiyoshi, K.
    Kagawa, Y.
    Kato, T.
    Oki, F.
    Ando, T.
    Hagiwara, Y.
    Ohashi, Y.
    Shitara, K.
    ANNALS OF ONCOLOGY, 2018, 29 : 95 - 95
  • [3] REVERCE: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan-Biomarker analysis.
    Tsuji, Yasushi
    Shitara, Kohei
    Yamanaka, Takeharu
    Denda, Tadamichi
    Shinozaki, Katsunori
    Komatsu, Yoshito
    Kobayashi, Yoshimitsu
    Furuse, Junji
    Okuda, Hiroyuki
    Asayama, Masako
    Akiyoshi, Kohei
    Kagawa, Yoshinori
    Kato, Takeshi
    Oki, Eiji
    Ando, Takashi
    Hagiwara, Yasuhiro
    Ohashi, Yasuo
    Yoshino, Takayuki
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [4] Randomized phase II study of regorafenib followed by cetuximab versus reverse sequence for wild-type KRAS metastatic colorectal cancer previously treated with fluoropyrimidine, oxaliplatin, and irinotecan (REVERCE).
    Shitara, Kohei
    Yamazaki, Kentaro
    Uetake, Hiroyuki
    Kato, Takeshi
    Oki, Eiji
    Yamanaka, Takeharu
    Ohashl, Yasuo
    Yoshino, Takayukl
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [5] REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients
    Shitara, K.
    Yamanaka, T.
    Denda, T.
    Tsuji, Y.
    Shinozaki, K.
    Komatsu, Y.
    Kobayashi, Y.
    Furuse, J.
    Okuda, H.
    Asayama, M.
    Akiyoshi, K.
    Kagawa, Y.
    Kato, T.
    Oki, E.
    Ando, T.
    Hagiwara, Y.
    Ohashi, Y.
    Yoshino, T.
    ANNALS OF ONCOLOGY, 2019, 30 (02) : 259 - 265
  • [6] REVERCEII (ACCRU-GI-1809): A randomized phase II study of regorafenib followed by anti-EGFR monoclonal antibody therapy versus the reverse sequencing for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin and irinotecan
    Ahn, Daniel H.
    Ou, Fang-Shu
    Sonbol, Bassam Bassam
    Wender, Donald
    Klute, Kelsey
    Jin, Zhaohui
    Jones, Jeremy Clifton
    Ulrich, Angela
    Waechter, Blake
    Young, Heather
    Weinberg, Benjamin Adam
    Lenz, Heinz-Josef
    Strickler, John H.
    Bekaii-Saab, Tanios S.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [7] REVERCE: A Randomized Phase II trial of Regorafenib - Cetuximab for mCRC previously treated with chemotherapy
    Kagawa, Yoshinori
    Shitara, Kohei
    Yamanaka, Takeharu
    Denda, Tadamichi
    Tsuji, Yasushi
    Shinozaki, Katsunori
    Komatsu, Yoshito
    Kobayashi, Yoshimitsu
    Furuse, Junji
    Kato, Takeshi
    Ohashi, Yasuo
    Yoshino, Takayuki
    CANCER SCIENCE, 2018, 109 : 307 - 307
  • [8] A phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidine, oxaliplatin, and bevacizumab
    Nakajima, Go
    Kuramochi, Hidekazu
    Ando, Masayuki
    Itabashi, Michio
    Kawakami, Kazuyuki
    Hamano, Mie
    Hirai, Eiichi
    Lino, Takayuki
    Yokomizo, Hajime
    Okuyama, Ryuji
    Araida, Tatsuo
    Yoshimatsu, Kazuhiko
    Kameoka, Shingo
    Hayashi, Kazuhiko
    CANCER RESEARCH, 2016, 76
  • [9] Phase I study of weekly oxaliplatin plus irinotecan in previously treated patients with metastatic colorectal cancer
    Kemeny, N
    Tong, W
    Gonen, M
    Stockman, J
    Di Lauro, C
    Teitcher, J
    White, P
    Price, C
    Saltz, L
    Sharma, S
    Graham, MA
    ANNALS OF ONCOLOGY, 2002, 13 (09) : 1490 - 1496
  • [10] EPIC:: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer
    Sobrero, Alberto F.
    Maurel, Joan
    Fehrenbacher, Louis
    Scheithauer, Werner
    Abubakr, Yousif A.
    Lutz, Manfred P.
    Vega-Villegas, M. Eugenia
    Eng, Cathy
    Steinhauer, Ernst U.
    Prausova, Jana
    Lenz, Heinz-Josef
    Borg, Christophe
    Middleton, Gary
    Kroening, Hendrik
    Luppi, Gabriele
    Kisker, Oliver
    Zubel, Angela
    Langer, Christiane
    Kopit, Justin
    Burris, Howard A., III
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (14) : 2311 - 2319
12345